North America small molecule API market is projected to grow by 5.3% annually in the forecast period and reach $112.5 billion by 2032, driven by the increasing incidences of diseases, the development of high-potency small molecule APIs, patents expiry of the top-selling pharmaceuticals, the increasing technological developments in manufacturing sector, and a surging healthcare expenditure.
Highlighted with 60 tables and 48 figures, this 125-page report "North America Small Molecule API Market 2022-2032 by Source (Synthetic, Semi-synthetic, Natural), Product Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity" is based on comprehensive research of the entire North America small molecule API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America small molecule API market in every aspect of the classification from perspectives of Source, Product Type, Therapeutic Area, Application, Manufacturer Type, and Country.
Based on Source, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Synthetic API
o Branded Synthetic API
o Generic Synthetic API
• Semi-synthetic API
• Natural Origin
Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Standard API
• High Potency API (HPAPI)
o Branded HPAPI
o Generic HPAPI
By Therapeutic Area, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Metabolic Diseases
• Other Therapeutic Areas
By Application, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Clinical Use
• Commercial Use
By Manufacturer Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pharmaceutical Companies
• CMOs
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Product Type, Therapeutic Area, and Manufacturer Type over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Aurobindo Pharma Ltd.
Cambrex Corporation
Catalent Inc.
Dr. Reddy's Laboratories
GlaxoSmithKline plc
Lonza Group
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Wuxi AppTec Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 24
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 26
2.2 Major Growth Drivers 30
2.3 Market Restraints and Challenges 34
2.4 Emerging Opportunities and Market Trends 37
2.5 Porter's Fiver Forces Analysis 41
3 Segmentation of North America Market by Source 45
3.1 Market Overview by Source 45
3.2 Synthetic API 47
3.2.1 Branded Synthetic API 48
3.2.2 Generic Synthetic API 49
3.3 Semi-synthetic API 50
3.4 Natural Origin 51
4 Segmentation of North America Market by Product Type 52
4.1 Market Overview by Product Type 52
4.2 Standard API 54
4.3 High Potency API (HPAPI) 55
4.3.1 Branded HPAPI 56
4.3.2 Generic HPAPI 57
5 Segmentation of North America Market by Therapeutic Area 58
5.1 Market Overview by Therapeutic Area 58
5.2 Infectious Diseases 60
5.3 Oncology 61
5.4 Ophthalmology 62
5.5 Cardiovascular Disorders 63
5.6 Central Nervous System 64
5.7 Respiratory Disorders 65
5.8 Metabolic Diseases 66
5.9 Other Therapeutic Areas 67
6 Segmentation of North America Market by Application 68
6.1 Market Overview by Application 68
6.2 Clinical Use 70
6.3 Commercial Use 71
7 Segmentation of North America Market by Manufacturer Type 72
7.1 Market Overview by Manufacturer Type 72
7.2 Pharmaceutical Companies 74
7.3 CMOs 76
8 North America Market 2022-2032 by Country 78
8.1 Overview of North America Market 78
8.2 U.S. 81
8.3 Canada 84
8.4 Mexico 86
9 Competitive Landscape 88
9.1 Overview of Key Vendors 88
9.2 New Product Launch, Partnership, Investment, and M&A 91
9.3 Company Profiles 92
Aurobindo Pharma Ltd. 92
Cambrex Corporation 94
Catalent Inc. 95
Dr. Reddy's Laboratories 98
GlaxoSmithKline plc 101
Lonza Group 105
Merck & Co., Inc. 108
Mylan N.V. 110
Novartis AG 112
Pfizer Inc. 114
Sun Pharmaceutical Industries Ltd. 118
Teva Pharmaceutical Industries Ltd. 121
Wuxi AppTec Co., Ltd. 123
RELATED REPORTS 125
Price : US$ 3500 |
Date : Nov 2024 |
Category : Services |
Pages : 120 |